Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01460628 · ClinicalTrials.gov registry record · Phase 4
Effect of Nuvigil on Fatigue
A Phase 4 study of Menopause, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01460628: Completed Phase 4 study of Menopause, sponsored by Massachusetts General Hospital.
NCT01460628 is a Phase 4 study of Menopause that has completed, run by Massachusetts General Hospital. The registered enrollment target is 25 participants, below the 9,394-participant average among 54 other Menopause trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01460628, a Phase 4 study of Menopause, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if armodafinil improves quality of life and is an effective treatment of fatigue in symptomatic perimenopausal and postmenopausal women.
Primary Outcome
This is a widely used self-report instrument to determine differences in quality of life among menopausal women and to measure changes in their quality of life over time. Four domain scores are calculated from the 29-item instrument. The physical domain subscale has 16 questions and a range from 0-8 with higher scores indicating worse symptoms.
Conditions Studied
Interventions
- DRUG Armodafinil
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-12 |
| Phase | Phase 4 |
What the finished NCT01460628 record still lists
NCT01460628 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 9,394-participant average among 54 other Menopause trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Menopause appearing as the primary indexed condition, and to 1 intervention - of which Armodafinil is the first listed.
NCT01460628 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01460628 about?
NCT01460628 is a clinical study titled "Effect of Nuvigil on Fatigue". The purpose of this study is to determine if armodafinil improves quality of life and is an effective treatment of fatigue in symptomatic perimenopausal and postmenopausal women.
What is the current status of trial NCT01460628?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2011-10. Estimated completion is 2013-12.
What conditions does trial NCT01460628 study?
This clinical trial studies the following conditions: Menopause.
What interventions are being tested in trial NCT01460628?
The interventions under investigation include: Armodafinil (DRUG).
Who is sponsoring clinical trial NCT01460628?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01460628 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01460628's enrollment target sits among peer trials
25 46th of 54 higher than 9 of 54 other Menopause trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Menopause trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cardiometabolic Consequences of the Loss of Ovarian Function
RECRUITING · Phase 4
-
Role of Menopause in Thermoregulation
RECRUITING · Phase 4
-
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
RECRUITING · Phase 4
-
Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)
ACTIVE NOT RECRUITING · Phase 4
-
Hormone Estradiol Replacement Therapy Additional Herbals
COMPLETED · Phase 4
-
Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia